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Abstract
Platelets respond to vascular damage and contribute to inflammation, but their role in the neurodegenerative diseases is
unknown. We found that the systemic administration of brain lipid rafts induced a massive platelet activation and
degranulation resulting in a life-threatening anaphylactic-like response in mice. Platelets were engaged by the sialated
glycosphingolipids (gangliosides) integrated in the rigid structures of astroglial and neuronal lipid rafts. The brain-abundant
gangliosides GT1b and GQ1b were specifically recognized by the platelets and this recognition involved multiple receptors
with P-selectin (CD62P) playing the central role. During the neuroinflammation, platelets accumulated in the central nervous
system parenchyma, acquired an activated phenotype and secreted proinflammatory factors, thereby triggering immune
response cascades. This study determines a new role of platelets which directly recognize a neuronal damage and
communicate with the cells of the immune system in the pathogenesis of neurodegenerative diseases.
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Introduction
The inflammation in the central nervous system (CNS) is a
complex and understudied process, underlying numerous nosol-
ogies with a high socioeconomic impact worldwide. With the
current focus on the disease prevention it is of vital importance to
dissect the initiation of a neuronal damage and define the specific
triggers and first-line responders. Platelets, or thrombocytes, are
small (2–3 mm in diameter) non-nucleated cells produced by
megakaryocytes through a budding process which takes place
primarily in the bone marrow [1,2]. In the peripheral blood
platelets outnumber leukocytes almost 100-fold and are known to
play a pivotal role in thrombosis and hemostasis in response to a
blood vessel injury. There is a growing body of knowledge
demonstrating that platelets contribute to the inflammation in a
number of pathologic processes including infection, atherosclero-
sis, and cancer metastasis [3–7]. The important role of platelets
was reported in the pathogenesis of arthritis where they recognize
the exposed collagen and produce microparticles upon activation
[8]. The platelets have also been reported as the first line of
defense against blood-born pathogens such as Listeria monocytogenes
[9]. A number of molecular structures which are exposed to the
blood stream after the disruption of the endothelial cell integrity
are recognized by platelets. These structures include von Will-
ebrand factor, collagen, laminin, vitronectin and fibrinogen. A
number of specific receptors expressed by platelets including
CD42, and integrins consisting of various a light chains and b1
and b3 heavy chains are operative in the recognition of these
factors [10].
The role of platelets is well established in cardiovascular
pathologies and cancer but it is poorly understood in neurologic
diseases [11,12]. The activation of platelets has been reported in
Alzheimer’s disease (AD) and multiple sclerosis (MS) [13–17], but
little is known about the details of such activation. The platelet
activation during the neuroinflammation was associated with the
interaction between platelets and damaged endothelial cells and
leukocytes [18,19]. The presence of specific structures in the CNS,
which can be directly recognized by platelets, has not been
reported.
In contrast to other tissues, the CNS is separated from the rest of
the body by the blood brain barrier (BBB) made of the tight
junctions of brain endothelial and astroglial cells [20]. Neuronal
and astroglial cells are functionally integrated with vascular
endothelial cells into so called ‘‘neurovascular units’’ [20–22],
and disruption of the the BBB is a hallmark of many
neurodegenerative and neuroinflammatory diseases, including
MS [23]. In our work we focused on the roles of the neurovascular
unit damage and mechanisms of the resultant platelet activation.
Our analysis revealed that platelets recognize the sialated
gangliosides in the lipid rafts on the surface of astroglial and
neuronal cells, which was important for the development of the
experimental autoimmune encephalomyelitis (EAE), an animal
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1*model of neuroinflammatory and neurodegenerative disease such
as MS. This study presents a significant step forward in
understanding the new types of the neuronal damage signals that
involve platelets as effectors.
Results
The Brain Lipid Rafts Induce a Platelet-mediated
Anaphylactic-like Reaction
In order to study the interactions of blood cells with the
structures of the damaged neuronal tissue, we injected the whole
brain homogenate intravenously into inbred unmanipulated (non-
immunized or naı ¨ve) mice. We observed a reaction with the typical
features of an anaphylactic shock including the tachycardia,
dyspnea and hypothermia (Figure S1 in File S1). To quantita-
tively assess the symptoms of the observed anaphylactic-like
reaction we used an anaphylactic score system: 1 - restless
behavior; 2 -loss of consciousness; 3 - dyspnea; 4 - death (see
Methods). The administration of the brain lipid rafts resulted in 2.3-
fold increase in the histamine level in the plasma above the
background level, suggesting a quick release of this mediator. The
intravenous injection of 1 ml saline substantially ameliorated the
symptoms [24] by increasing the volume of the circulating blood
and relieving tachycardia, as did the anti-histamine drug
pyrilamine by decreasing the anaphylactic score from 1.860.2
to 0.860.1, further suggesting the involvement of histamine as a
mediator of the observed phenomena. The animals that died from
the anaphylactic-like reaction did not present necrotic areas in the
lungs, a typical sign of thromboembolism. In the subsequent
experiments we determined that the shock inducing component
was contained in the brain homogenate supernatant centrifuged at
low speed (400 g), in agreement with the study by Zibitsker
published in 1961 [25]. The size of the component was identified
to be between 0.2–0.4 m and 0.05 m. The filtered supernatant was
sensitive to boiling and treatment with 1% Tween 40, but not to
freezing at 220uCo r270
o, sonication or treatment with 0.5%
Triton X-100 (Table S1 in File S1). The resistance to Triton X-
100 identified the brain-derived particles which induced the
anaphylactic-like reaction as ‘‘lipid rafts.’’ To confirm that the
anaphylactic-like reaction was caused by the brain lipid rafts, we
isolated them by homogenizing the brain in PBS with 0.5% Triton
X-100 and found that the in vivo injection of these lipid rafts caused
the anaphylactic-like reaction similar to that of 0.2m filtered
supernatants described above. Subsequently, the brain homoge-
nates prepared with 0.5% Triton X-100 were fractionated on a
sucrose gradient and analyzed. The anaphilactogenic fractions in
the sucrose gradient were particularly enriched in phospholipids
and cholesterol and had a low content of the transferin receptor,
which are the key features of lipid rafts (Figure S2 in File S1).
Regarding the cellular arm of the response we found that the
depletion of platelets completely abrogated the anaphylactic-like
reaction whereas no effect was observed when macrophages or
granulocytes were depleted, or in the mice genetically deficient for
mast cells, B cells, or T/B cells (Figure 1A and Table S1 in File
S1). Finally we performed a differential diagnosis of the clinical
and laboratory features of the anaphylactic-like reaction induced
by the brain lipid rafts and those of the thromboembolism induced
by the i.v. administration of thrombin [26] (Table S3 in File S1;
Video S1 and Video S2). In this experiment we demonstrated
that the administration of lipid rafts caused anaphylactic-like
reaction that is symptomatically different form the thromboem-
bolism induced by the injection of thrombin. Collectively the data
suggest that the administration of brain lipid rafts results in the
anaphylactic-like reaction mediated by platelets in mice.
Sialated Gangliosides Induce an Anaphylactic-like
Reaction
To understand which components of the lipid rafts are
responsible for the platelet mediated anaphylactic-like reaction
we enzymatically cleaved lipids, carbohydrates or proteins on the
lipid rafts obtained by the size filtration (0.2 m) and by solubility in
0.5% Triton X-100 (Figure 1B; Table S4 in File S1). The
treatment of brain lipid rafts with lipases (phospholipase and
sphingomyelinase) or neuraminidase (which specifically removes
the sialic acid) completely inhibited the anaphylactic response. In
addition, the cholesterol-depleting agents MbCD and saponin,
and b-galactosidase reduced the anaphylactic-like reaction by
,80%. Fucosidase (removes fucose) and endoglycosidases (which
specifically deglycosylate proteins but not lipids; see Table S2 in
File S1) had no effect. The treatment with proteolytic enzymes
(trypsin and proteinase K) had a minimal effect on the lipid rafts
isolated by the size filtration and decreased the anaphylactic score
in the lipid rafts isolated with Triton 0.5% X-100 by ,50%
(Figure 1B; Table S2 in File S1). Collectively these findings
suggest that the sialated glycosphingolipids (gangliosides) rather
than the glycosylated proteins are the primary moieties recognized
by the platelets. Indeed, the gangliosides together with other
sphingolipids (e.g., sphingomyelin), phospholipids and cholesterol
are found within lipid rafts and have a sialated galactose within the
glycopolymer [27]. Interestingly, the injection of the ‘‘naked’’
sialated gangliosides (GM1, GD3 and GT1b) did not result in an
anaphylactic-like reaction. In addition to that, removing choles-
terol (using saponin or MbCD) that is necessary for the structural
stability of lipid rafts decreased the ability of the rafts to cause the
anaphylaxis by ,80%. Taken together these results indicate that
platelets recognize gangliosides only within the intact structure of
lipid rafts.
Gangliosides are present in many tissues, but the most abundant
source is the brain [28]. We isolated lipid rafts from different
organs and normalized the amount of injected rafts to the initial
wet weight of the tissue. As shown in Figure 1C, only the lipid
rafts from the brain and spinal cord triggered the anaphylactic-like
reaction in-vivo. Since the lipid rafts were isolated from the same
amount of tissue, we hypothesized that the amount of lipid rafts in
organs varies. Indeed, when we measured the concentration of
phospholipids, we found out that the internal organs had less lipid
rafts compared to the brain (Table S4 in File S1). When the
amount of the injected rafts was normalized to the concentration
of phospholipids, we found that the lipid rafts from the testis,
pancreas, lungs and heart also evoked the anaphylactic-like
reaction (Figure 1D, Table S4 in File S1). Of interest is that
the testis and pancreas are considered to be the ‘‘barrier’’ organs
similar to the CNS, whereas the heart is prone to ischemia, an
attribute of inflammation and injury, similar to a stroke in the
brain. In summary, these data suggest that: 1) the brain and spinal
cord have the highest concentration of the lipid rafts that are
recognized by the platelets, and 2) the organized structures of
sialated gangliosides within the lipid rafts are required for the
recognition of these structures by the platelets leading to
anaphylaxis.
The Lipid Rafts on Astrocytes and Neurons Induce an
Anaphylactic-like Reaction
To find the cellular source of the lipid rafts responsible for the
platelet-mediated anaphylactic-like reaction, we tested the cell
lines and primary cells from the CNS. The lipid rafts from the cells
of the neuronal and astroglial origin caused an anaphylactic-like
reaction, whereas the rafts from the cells of oligodendroglial and
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rafts described above, the enzymatic analysis demonstrated that
the lipid rafts from astroglial cells induced the anaphylactic-like
reaction in mice in a sialoganglioside-dependent fashion. (Figure
S3 in File S1). Of note, the lipid rafts from the neuroblasoma cell
line NIE115 were also anaphylactogenic, whereas from the line
Neuro2A were not. Neuro2A is deficient in sialated gangliosides
including GD3 and GQ [29] which is consistent with our findings
that the sialated gangliosides are recognized by the platelets during
the induction of the anaphylactic-like reaction. To compare the
lipid rafts from the species other than mice, we injected lipid rafts
from human, rat, and fish brains into mice. The anaphylaxis was
observed with human and rat, but not fish brains. We then isolated
the lipid rafts separately from the white and gray matter of the
human autopsy brain samples. The gray matter (enriched with
astrocytes and neurons) lipid rafts had more than a 2-fold higher
effect when compared with the white matter (enriched with
oligodendrocytes) rafts (Figure 2A). Similarly, the lipid rafts
isolated on a sucrose gradient from the rat brain myelin fraction
(enriched in oligodendrocytes and normalized by the raft content
were 3-fold less anaphylactogenic compared to the lipid rafts
isolated from the whole rat brain (Figure 2A). In addition, we
found that the rat cortical neurons and astrocytes caused
anaphylaxis, whereas the rat oligodenodrocytes did not (not
shown).
The Lipid Rafts of Astroglial and Neuronal Cells Carry
GM1, GD3, GT1b and GQ
It has been reported that the subunit B of Cholera toxin (CTB)
binds GM1 ganglioside, the ubiquitous marker of lipid rafts [30].
We visualized lipid rafts with fluorescent CTB using the imaging
cytometry and found that the brain lipid rafts had round compact
areas ,0.5 m or less in diameter with bright staining for CTB
(Figure 2B, Brain lipid rafts). These lipid rafts were also present
on the anaphylactogenic neuroblastoma cell line NIE115
(Figure 2B, Neuroblastoma). We then examined the expression
of several sialated gangliosides GM1, GM2, GD3, GD1b, GT1b
and GQ on the following: the brain lipid rafts, neurons,
neuroblastoma cell line, astrocytes and astroglial cell line (Figure
S4 in File S1). All the lipid rafts (both from the brain and the cells
of the neuronal/astroglial origin) we tested expressed the following
four gangliosides: GM1, GD3, GT1b and GQ.
Lipid Rafts are Co-localized with Perivascular Astrocytes
and Neurons
We investigated the anatomic location of lipid rafts in the mouse
and human brains by staining frozen sections with fluorescent
CTB. Although lipid rafts could be found throughout the brain,
the brightest staining occurred around the long pipe-like structures
of the brain capillaries (Figure 2C, top images). Using single
staining for GM1 on the lipid rafts (CTB), and double staining for
the lipid rafts (CTB) and neurons (MAP2), or astrocytes (GFAP),
we found GM1 positive astrocytes and neurons surrounding the
brain capillaries and blood vessels (Figure 2C, middle images).
We also found areas of bright staining for GM1 on the astrocytes
underlying the brain subpial (superficial) blood vessels (Figure 2C,
bottom images). To confirm the presence of lipid rafts on the
neuronal cells ex-vivo, we used Thy1-YFP reporter mice that have
neuronal bodies and axons (including neuronal endings) geneti-
cally labeled with YFP [31]. The YFP positive fluorescent
neuronal axons were also GM1 positive in the brain areas close
to the blood vessels and capillaries, known as neurovascular units
(Figure S5 in File S1). In contrast, we found no co-localization of
GM1 staining with the staining for basal membranes, endothelial
cells or pericytes either in the mouse or human brains (Figure S6
in File S1). Thus, lipid rafts are preferentially detected on the
astrocytes and neurons of neurovascular units of the intact brain.
Platelets Interact with Natural and Model Lipid Rafts
Since the intravenous injection of the brain lipid rafts led to the
anaphylaxis mediated by platelets and required sialated ganglio-
sides on the lipid rafts (Figure 1), we hypothesized that platelets
first adhere to lipid rafts and then degranulate to induce an
anaphylactic-like reaction. Our hypothesis was supported by the
reports of a massive platelets degranulation caused by the
intravenous administration of a radiographic contrast media in
the humans [32] or by lyophilized whole bacterial cells in mice
causing an anaphylactic shock [33]. To test whether platelets
interact with lipid rafts in vitro, we mixed the platelets isolated from
DsRed transgenic mice that ubiquitously express the red
fluorescent protein under the actin promoter (Figure 3A, Platelets
only) with the brain lipid rafts from naı ¨ve inbred mice (pre-stained
with fluorescent CTB) and after 3 minutes the samples were fixed
and analyzed by the imaging cytometry. We found that the
platelets (red) adhered to the lipid rafts (green) (Figure 3A,
Platelets+Brain lipid rafts). The co-incubation of mouse platelets
with either the mouse or human brain lipid rafts in vitro resulted in
the release (7–10 fold upregulation) of serotonin (Figure S7 in
File S1), PF4/CXCL4 and the anaphyloctogenic mediator
histamine (not shown), a hallmark of the platelet degranulation.
In a reverse experiment we demonstrated that the incubation of
human platelets with human or mouse lipid rafts also resulted in a
serotonin release (Figure S7 in File S1) suggesting that a similar
mechanism of platelet degranulation in response to the presence of
lipid rafts takes place in humans. In addition, we found that the
interaction of human or mouse platelets with the brain lipid rafts
in vitro resulted in the platelet shape change and aggregation
(Figure S8 in File S1). We also observed the upregulation of the
Figure 1. Role of platelets and lipid rafts in the induction of anaphylaxis. (A) The lipid rafts were isolated by homogenization of the brain in
PBS with 0.5% Triton X-100 and injected i.v. to induce anaphylaxis. The animals were observed for ten minutes as described in Methods. The role of
platelets and white blood cell subsets were assessed by using an antibody (for depletion of platelets and granulocytes), lyposomes with
bisphosphonate clodronate (for depletion of macrophages), or the CD11b-DTR transgenic mice, and genetically deficient animals (mast cells, B cells,
T/B cells) as described in Methods.( B) The effect of enzymatic treatment of brain lipid rafts on their ability to induce anaphylaxis. The brain lipid rafts
were obtained by size filtration (0.2 m filtered) or solubility in 0.5% Triton X-100 (0.5% Triton X-100) as described in Methods. The brain lipid rafts were
treated with lipases (sphingomyelinase and phospholipase), enzymes that cleave glycopolymers (neuraminidase, b-galactosidase and fucosidase),
cholesterol depleting agents (saponin and MbCD) and proteolytic enzymes (trypsin and proteinase K) and injected i.v. for the assessment of
anaphylaxis. The non-treated brain lipid rafts were used as a control (no treatment). The animals were observed for ten minutes as described in
Methods.( C,D) The ability of lipid rafts from different organs to cause anaphylaxis. The lipid rafts were isolated from the spinal cord, brain, adrenal
gland, pancreas, ovaries, kidney, spleen, thymus, eyes, testis, lungs, liver and heart by the homogenization of tissues in PBS with 0.5% Triton X-100.
The amount of i.v. injected lipid rafts was normalized according to the weight of the wet tissue (c) or concentration of phospholipids (d) as described
in Methods. The animals were observed for ten minutes as described in Methods.I nA–D, the maximum clinical anaphylaxis score (Mean 6 S.E.) of the
total number of animals from three separate experiments with 5–6 mice per group in each experiment is shown.l.
doi:10.1371/journal.pone.0058979.g001
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PLOS ONE | www.plosone.org 4 March 2013 | Volume 8 | Issue 3 | e58979Figure 2. Origin and localization of brain lipid rafts. (A) The lipid rafts were isolated from the primary cultures, cell lines, human brain gray and
white matter, or rat whole brain and rat brain myelin fractions. The lipid rafts were injected i.v. and anaphylaxis was scored (see Figure 1). (B) The
brain homogenates and neuronal line cells lipid rafts were stained for a GM1 marker of lipid rafts (CTB) and visualized by Imaging Cytometry (green).
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File S1), Ca
2+ influx, and secretion of IL-1a (Figure S9 in File
S1). This suggests that platelets become activated and degranulate
upon the interaction with lipid rafts.
To understand the role of gangliosides in the lipid raft-induced
platelet adhesion and degranulation we created artificial lipid rafts
with various integrated gangliosides and then tested the ability of
these lipid rafts to induce anaphylaxis. We found that the i.v.
injection of the model rafts with sialated gangliosides resulted in an
anaphylactic-like reaction, with ganglioside GT1b eliciting the
strongest and GD1b the weakest effect. At the same time, the lipid
rafts without gangliosides (Bkg) or containing an asialated GM1
ganglioside (aGM1) or galactocerebroside (GC) did not induce
anaphylaxis (Figure 3B).
The role of ganglioside GD3 has been reported in the platelet
adhesion [34]. We tested the gangliosides described above to find
that platelets primarily adhered to GD3 with some binding to
GT1b and GQ1b, as well as to GM1 and GM2 (Figure 3C). Next
we assessed the ability of artificial lipid rafts with selected
gangliosides to cause the platelet degranulation in vitro as
determined by the serotonin release. GT1b and GQ1b caused
the most prominent release of serotonin at a level similar to the
natural brain lipid rafts. The model lipid rafts without gangliosides
(Bkg) or with asialated GM1 (aGM1) or galactocerebroside (GC)
did not cause a serotonin release above the background levels
(Figure 3D).
Platelets Receptors Recognize Sialated Gangliosides
Since platelets recognize sialated gangliosides within the lipid
rafts, we carried out experiments to identify the receptors
responsible for this interaction. In the first series of the experiments
we blocked the receptors with antibodies or used the mice
genetically deficient for the known platelet receptors and other
factors (including integrins, FcR gamma chain, scavenger recep-
tors; see Table S5 in File S1), but found that none of these
molecules were responsible for the anaphylactic-like reaction. Our
results (above) indicated the involvement of the receptors that
specifically recognize the sialic acid on charbohydrate polymers.
Indeed, two classes of receptors are known to recognize the
sialated carbohydrate structures, including gangliosides: lectins
and siglecs [35]. Platelets are known to express P-selectin (CD62P)
[10]; the expression of siglecs on the platelets has not been
examined. In addition, the adhesion molecules of the immuno-
globulin family can potentially bind sialated carbohydrates [36].
We found that mouse platelets express two activating siglec
receptors, Siglec-H and Siglec-15 (Figure S10a in File S1). Of
the examined adhesion molecules, the mouse platelets only
expressed ALCAM/CD166 (Figure S10a in File S1)a s
determined by FACS. We confirmed the expression of ALCAM
on the mouse and human platelets by Western blot (Figure S10b
in File S1). We also examined the expression of adhesion
molecules in the human platelets by the flow cytometry and found
that the human platelets also expressed ALCAM (Figure S10c in
File S1). We detected the baseline level of expression of P-selectin
on ex-vivo isolated platelets in the platelet rich plasma of mice and
human (Figure S10a,c in File S1), which could be explained by
a partial activation of platelets during the isolation and antibody
staining; however P-selectin was substantially unregulated when
the platelets were activated in vitro (not shown).
In the second series of the experiments we tested whether an
antibody to CD62P, Siglec-H, Siglec-15 or CD166 could block the
ganglioside GT1b or GD3-mediated serotonin release by the
platelets. The separate anti-CD62P and anti-CD166 treatment
partially decreased the serotonin release and the simultaneous
addition of the Abs showed the most inhibition (Figure 4A). The
anti-Siglec-15 and anti-Siglec-H antibodies did not affect the
serotonin release in our assays, suggesting that either these
receptors do not play a role in recognizing the sialated gangliosides
or the antibodies failed to block the interaction. Finally we tested
whether the classic platelet receptors GPIb/CD42 play a role in
the recognition of the brain lipid rafts and found that the blocking
antibodies to CD42 failed to block the serotonin release in vitro
induced by the natural and model lipid rafts (not shown).
In vivo, the systemic (i.v.) injection of both anti-CD62P and anti-
CD166 Abs substantially ameliorated the anaphylaxis induced by
the model lipid rafts containing GD3 or GT1b (Figure 4B). Also,
the anaphylaxis was inhibited by the pretreatment of the GD3 or
GT1b-containing rafts with a soluble CD166-Fc fusion protein to
compete with the cell-surface CD166 (Figure 4B). Using
genetically modified mice we demonstrated that the CD62P
deficient mice had a lower anaphylactic score when treated with
lipid rafts compared to the wild type B6 mice (Figure 4B,
CD62P
2/2). On the other hand, the CD166 deficient mice had
similar or higher anaphylactic scores (Figure 4C, CD166
2/2).
Those were unexpected results, since antibodies to CD166
decreased the anaphylaxis (Figure 4B). We hypothesized that
CD62P binds sialated glycoepitopes on gangliosides directly,
whereas ALCAM interacts with CD62P to inactivate or mask it
as was reported for several siglecs (e.g. CD45 binds and inactivates
Siglec-2) [37]. ALCAM has mono- and di- sialated glycoepitopes
in the structure that closely mimics gangliosides [29] and these
regions of ALCAM could potentially bind CD62P and prevent its
interaction with the gangliosides in the lipid rafts. In our
experiments we showed that the CD62P-Fc fusion protein did
bind the mono- and di- sialated glycoepitopes (39-sialyllactose and
a2,8-disialic acid) that are present on the gangliosides (Figure 4D),
whereas ALCAM did not (not shown). We also found that
ALCAM could bind CD62P-Fc (Figure 4E), suggesting that
ALCAM could interfere with the activation of platelets via binding
to the cell-surface CD62P. This explains why the antibodies to
CD166 and CD62P blocked the platelet-raft interactions
(Figure 4F). Since P-selectin is expressed on the surface of the
activated platelets, we believe other receptors that recognize the
sialic acid (e.g. Siglec-H, Siglec-15) are involved in the initiation of
the lipid rafts recognition by the platelets with the outcome of the
platelets activation, expression of P-selectin and development of
anaphylaxis (Figure 4F).
Platelets Interact with Lipid Rafts in the CNS during
Neuroinflammation
We next investigated the platelet-lipid raft interaction in the
CNS during EAE, a classic model of inflammation in the CNS.
We found that CD41
+CD61
+ platelets were present in the normal
brain (14% of the brain homogenate platelet-rich supernatant),
(C) The sections of the mouse (left) and human (right) brains stained with CTB (top two images, green). In the middle four images, the mouse brain
sections stained with CTB show the lipid rafts around the brain capillaries (left) and blood vessels (right); same with double-staining for the neuronal
(MAP2; left) and astroglial (GFAP; right) (both red) markers. Two bottom images depict areas around the brain blood vessels under pia matter
(superficial blood vessels) single stained with CTB (left, green) or double stained with CTB/GFAP (right; CTB in green, GFAP in red). DAPI staining for
the cell nuclei is shown in blue. Abbreviations: BC – brain capillary, BV-blood vessel, SBV-superficial blood vessel.
doi:10.1371/journal.pone.0058979.g002
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PLOS ONE | www.plosone.org 6 March 2013 | Volume 8 | Issue 3 | e58979Figure 3. Unique composition of lipid rafts triggers platelets degranulation. (A) The platelets were isolated from the DsRed transgenic
mice, incubated with CTB-prestained brain lipid rafts for 3 minutes, fixed, washed and analyzed by Imaging Cytometry. Left, the bright field images
and platelets fluorescence is shown (red). Right, the platelets (red) interaction with brain lipid rafts (CTB, green) is shown. (B) The induction of
anaphylaxis by model lipid rafts in vivo. The model lipid rafts containing representative gangliosides (asyaloGM1, GM1, GM2, GD3, GD1b, GT1b, GQ),
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for the brain and day 4 for the spinal cord, there was a substantial
increase in the platelets counts (Figure 5A,B) and platelets
activated phenotype as determined by the CD62P upregulation
(not shown). On the frozen brain sections the CD41
+ platelets (red
staining) were detected in the perivascular spaces adjacent to the
GM1
+ brain lipid rafts (green staining) on day 6 after the EAE
induction (Figure 5C). We showed that the neuronal cells in the
Thy1-YFP reporter mice had lipid rafts (Figure S5 in File S1).
Accordingly, on day 6 of EAE in the Thy1-YFP reporter mice [31]
we registered the platelets (often in aggregates) in a close proximity
to the YFP
+ neuronal bodies and axons (Figure 5D; Figure S11
in File S1). The schematics of the platelets interaction with the
lipid rafts on astrocytes and neuronal endings of the perivascular
areas in the early stages of EAE is shown in Figure 5E. In the
more advanced stages of EAE (the peak of the disease), platelet
aggregates and single platelets were also located in the CNS
parenchyma close to the infiltrating CD11b
+ macrophages as
shown in Figure S12 in File S1.
To interact with lipid rafts on the surface of astrocytes and
neurons platelets must transmigrate into the CNS through the
tight junctions of the brain blood-vessel endothelial cells. It is
reported that platelets acquire the ability to move through the
activated endothelial cells during inflammation [38]. In the EAE
model, mice were immunized with MOG/CFA, and Pertussis toxin
(PTx) was administered on day 0 and 2 post-immunization. It has
been shown that PTx increases the endothelium permeability both
in vivo [39,40] and in vitro [41,42]. We found that both MOG/
CFA and PTx affect the BBB permeability on day 3 of EAE as
determined by the penetration of FITC-dextran from the blood
into the brain and spinal cord (not shown). Next we examined
whether the activation of endothelial cells with MOG/CFA and/
or PTx would increase the platelets transmigration in vitro.W e
created a model of the BBB by culturing astroglial cells on the
bottom of a transwell lower chamber, and endothelial cells on the
top side of the upper chamber filter as previously described [41,43]
(Figure 5E). Both MOG/CFA and PTx dramatically increased
the transmigration of platelets through the confluent monolayer of
endothelial cells towards the astroglial cells stratum (Figure 5F,G).
The percentage of transmigration into the lower chamber is shown
in Figure 5F.I nFigure 5G the relative quantity of the GFP
positive platelets (shown in green) on the astroglial layer (shown in
grey) in the lower chamber could be also estimated by eye as the
intensity of the green color and the area that is covered by the
GFP
+ platelets. Next, we examined the platelet reaction to the
brain lipid rafts in a EAE model. The mice with EAE had an
almost 2-fold higher anaphylaxis score after i.v. injection of brain
lipid rafts compared to the healthy controls (Figure S13a in File
S1). We hypothesized that this was related to the ongoing
processes of degranulation of platelets in the CNS during EAE. It
was reported that platelets accumulate and degranulate in the
lungs in the models of airway inflammation [44], while the CD41
+
microparticles and PF4/CXCL4 serve as markers of that
degranulation [8,45]. There was an increase of CD41
+ particles
in the plasma of mice with EAE (Figure S13b in File S1).
Moreover, mice with EAE had 25-fold higher levels of PF4 in the
serum compared to the healthy mice, and similar to the brain lipid
rafts-treated mice (Figure S13c in File S1). Thus, during
neuroinflammation, platelets interact with brain lipid rafts and
are highly sensitive to the degranulation in the periphery.
Recognition of Brain Lipid Rafts by Platelets Plays an
Important Role in the Development of
Neuroinflammation
We then asked whether the recognition of lipid rafts by platelets
played a role in the EAE progression. It was recently reported by
Langer et al. that platelets participate in the EAE pathogenesis by
recognizing integrins [19]; we hypothesized that the platelet-rafts
interactions also substantially contributed to the disease. To test
this hypothesis, we depleted the platelets or targeted ligands on the
lipid rafts to interfere with the platelet recognition of lipid rafts. We
depleted the platelets by injecting the anti-thrombocyte serum on
days 0, 2, 4 and 8. In addition, we treated animals with
neuroaminidase (NA) from C. Perfringers, which removes the
terminal sialic acid from glycoproteins and glycolipids by cleaving
the a2–3, a2–6, and a2–8 linkages, and also decreases the platelet
numbers. Finally, we used a LFA protein which specifically binds
the sialic acid [36,46] and CTB which binds GM1 ganglioside in
the lipid rafts [30,36] to prevent the interaction of the platelets
with lipid rafts. As shown in Figure 6A, we found that each of
these treatments ameliorated the EAE symptoms, demonstrating
that the platelet-lipid rafts interactions could play an important
role in EAE. However NA, CTB and LFA are considered to be
‘‘broad spectrum agents’’ that affect not only the platelet-raft
interactions but also other cells since the sialated glycoepitopes are
present on many cell types on both glycoproteins and glycolipids.
To exclude the non-specific effects of broad spectrum agents on
EAE, we used other approaches to specifically block the
interaction of platelets with lipid rafts on the astrocytes and
neurons. We used the A2B5 antibodies that bind ganglioside GQ
which is expressed specifically on the neuronal and astroglial cells
[47] and abundantly expressed in the brain lipid rafts (Figure S4
in File S1). We found that the treatment with an anti-GQ
antibody substantially ameliorated EAE (Figure 6B), and
decreased the infiltration of the CD4 T cells, lymphocytes and
macrophages in the CNS (Figure 6C,D). On the other hand, the
anti-GQ antibodies did not affect either the priming or effector
functions of the encephalitogenic T cells (Figure S14 in File S1),
suggesting that these antibodies did not have a non-specific direct
effect on immune cells. To confirm the data obtained with broad
spectrum agents (NA, CTB, LFA) and specific anti-GQ antibodies,
which block the platelet-rafts interactions, we used the mice
genetically deficient for sialyltranferase ST3Gal-V (GM3 Syn-
thase; gene: Siat9). These mice lack brain-specific gangliosides such
as GT1b and GQ; however the glicosylation of proteins remains
intact [48]. We found that the clinical manifestation of EAE was
substantially ameliorated in ST3Gal-V
2/2 when compared to
ST3Gal-V
+/2 and ST3Gal-V
+/+ control groups (Figure 6E). In
addition, the CNS inflammation was significantly reduced as
determined by the infiltration of lymphocytes, CD4 T cells and
macrophages on d21 after the EAE induction (Figure 6F). Thus
galactosylcerebroside (GC) or phosphatidylcholin (Bkg) were prepared and injected i.v. into the mice as described in Methods. The maximum clinical
anaphylaxis score (Mean 6 S.E.) of the total number of animals from three experiments with 4–5 mice per group in each experiment is shown. (C) The
platelet adhesion to gangliosides in vitro. AsialoGM1, GM1, GM2, GD3, GD1b, GT1b, GQ1b gangliosides, galactosylcerebroside (GC) or
phosphatidylcholin (Bkg) were adsorbed to flat-bottom 96-well plates and the adhesion of platelets to the ligands was measured. (D) The platelets
serotonin release induced by the model lipid rafts in vitro. The model lipid rafts were incubated with platelets and the concentration of serotonin in
the platelet-free supernatant was assessed. The brain lipid rafts (BrRft) served as a positive control. In c–d, the mean 6 S.E. of triplicate is shown. The
data is representative of two separate experiments.
doi:10.1371/journal.pone.0058979.g003
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PLOS ONE | www.plosone.org 9 March 2013 | Volume 8 | Issue 3 | e58979our study demonstrates that preventing the interaction between
platelets and brain-derived lipid rafts in the CNS by various
methods substantially ameliorated EAE.
Interaction of Platelets with Lipid Rafts in the CNS and
the Periphery Results in Induction of EAE in the Absence
of Pertussis toxin
To induce EAE, Pertussis toxin (PTx) is required in our model.
Although PTx may have multiple effects on immune cells, one of
the main mechanisms of its action is ‘‘opening’’ the BBB [49] and,
as we suggested, the facilitation of the platelet migration into the
CNS and their interaction with lipid rafts in situ. We investigated
whether the massive degranulation of platelets induced by lipid
rafts in the periphery or in the brain contributed to the EAE
induction in the absence of PTx. We immunized mice with MOG
and induced a systemic degranulation of the platelets by injecting
the brain lipid rafts i.v. on day 0 (Figure S15a in File S1). In a
separate experiment we induced the degranulation of platelets by
lipid rafts only in the brain by injecting purified platelets
intracranially (Figure S15b in File S1). We found that in both
cases EAE was induced in the absence of PTx. Thus we believe
that the injection of lipid rafts i.v. or platelets i.c. results in systemic
or local inflammatory responses and exacerbation of EAE as a
consequence of the interactions of platelets with brain gangliosides
in lipid rafts and the production of proinflammatory mediators
(e.g. PF4, IL-1a) by the platelets.
Interactions of Platelets with Lipid Rafts Result in
Microglia Activation, Transient Infiltration of
Macrophages and Lymphocytes in the CNS and
Granulocytosis in the Periphery
Based on the previous results we hypothesized that the
interaction of platelets with lipid rafts after a systemic administra-
tion of lipid rafts or during EAE resulted in the platelet
degranulation and the release of pro-inflammatory mediators,
which in turn contributed to the activation of the CNS-resident
innate immune cells and influx of leukocytes from the periphery.
To assess this we examined immune cells in the CNS and spleen
after the systemic administration of lipid rafts. We found that 10
minutes after the i.v. injection of brain lipid rafts, microglia
upregulated MHC class II and the numbers of macrophages were
increased both in the CNS and the spleen (Figure S16a,c,d in
File S1). Beginning at one hour, lymphocytes were also detected
in the CNS (Figure S16e in File S1). The percentage of the
activated microglia and the numbers of infiltrating lymphocytes
and macrophages returned to normal in the CNS by 48 hrs
(Figure 16a,c,e in File S1); the numbers of granulocytes
remained increased in the spleen after 48 hrs (Figure 16b in
File S1). Taken together, these data suggest that the interaction of
platelets with lipid rafts results in the activation of cells of immune
system both in the periphery and in the CNS.
Discussion
This study uncovers new ligands within the CNS which are
recognized by platelets, play an important role in sensing a
neuronal damage and participate in the induction and perpetu-
ation of inflammation in the CNS. These ligands are located in the
lipid rafts of astrocytes and neurons. We found that platelets bind
to the sialated gangliosides integrated into the brain lipid rafts
through a number of activating receptors on their surface, such as
CD62P, which results in the platelet activation and degranulation.
Our study demonstrates that sialated gangliosides rather than
glycoproteins are responsible for the interaction of platelets with
brain lipid rafts. First, the treatment of brain lipid rafts with
proteases decreased but did not completely inhibit the ability of
brain lipid rafts to cause an anaphylactic-like reaction in mice.
Second, only the lipid rafts containing sialated gangliosides
resulted in an anaphylactic-like reaction. Third, the treatment of
lipid rafts with the endoglycosidases that cleave N- and O-glucanes
(which deglycosilate proteins) did not inhibit the ability of the lipid
rafts to induce anaphylaxis. Fourth, the brain lipid rafts from other
mammalian species such as the human and rat also caused an
anaphylactic-like reaction in mice.
The composition of sialated glyco-chains in glycoproteins and
proteoglycans is highly polymorphic and varies considerably even
among closely related species such as human and chimp [50].
Given that there is a substantial difference in the protein structure
and glycosylation patterns between mice and human it is unlikely
that the human glycoproteins within the CNS lipid rafts would
cause anaphylaxis in mice. In contrast, the lipid composition of the
mammalian brain is conserved. We found that the brain lipid rafts
from an evolutionally remote species such as fish did not cause
anaphylaxis in mice. In contrast to mammals, the brain
endothelial cells in cartilaginous fishes do not have tight junctions
and the blood brain barrier is composed of a tight ring of
astrocytes [21,51]. Therefore, we believe that in the fish both
astrocytes and neurons of the neurovascular units do not have
specific sialated gangliosides which we found to be recognized by
platelets. Indeed, several studies suggested that the lipid compo-
sition and structure of gangliosides of the fish brain are different
from those of mammals [28]. In addition, we found that both
human and mouse lipid rafts caused a serotonin release from both
Figure 4. Lipid rafts engage platelet receptors specific to sialated gangliosides. (A) The effect of anti-CD62P and anti-CD166 mAbs on the
platelet serotonin release in response to the model lipid rafts containing GD3 and GT1b in vitro. The serotonin release was measured (see Figure 3)
in the presence of anti-CD62P and anti-CD166 mAbs. (B) The effect of anti-CD62P and anti-CD166 mAbs or the CD166-Fc fusion protein on the
platelet degranulation iduced by the model lipid rafts in vivo. Anti-CD62P and anti-CD166 mAbs were injected i.v., and the model lipid rafts
containing GD3 or GT1b gangliosides were injected 30 minutes later. The model lipid rafts containing GD3 or GT1b gangliosides were pre-treated
with the CD166-Fc protein and injected i.v. into naı ¨ve mice. All mice were then injected i.v. with the lipid rafts as described in Methods. The maximum
clinical anaphylactic score (Mean 6 S.E.) of the total number of animals from three experiments with four mice per group is shown (*, p,0.05; **,
p,0.01; when compared to non-treated animals). (C) The lipid rafts-induce anaphylaxis in wild-type (WT), CD62P (P-Selectin)- and CD166 (ALCAM)-
deficient mice. The model lipid rafts containing GT1b ganglioside were injected i.v. into naı ¨ve mice at 250, 125 or 60 ml per mouse. The maximum
clinical anaphylaxis score (Mean 6 S.E.) of the total number of animals from the three experiments with 4 mice per group in each experiment is
shown (*, p,0.05; **, p,0.01; when compared to wild-type animals). (D) Binding of CD62P-Fc fusion protein to lactose, 69-sialyllactose, 39-
sialyllactose and a2,8-disialic glycopolymers adsorbed onto 96 well plates. (E) Binding of CD62P-Fc fusion protein to recombinant ALCAM or BSA
(control) adsorbed onto 96 well plates. (F) Schematics of multiple receptors (CD62P, ALCAM, Siglec-H and Siglec-15) on the platelets and sialated
gangliosides on brain lipid rafts interaction. In addition to the interaction of sialic acid on gangliosides with CD62P and Siglecs, ALCAM has mono and
poly- sialated glycoepitopes that can be recognized by CD62P and Siglec-H/Siglec-15. The antibodies to ALCAM prevent binding of masked CD62P
and other siglec receptors on the platelets to the sialated gangliosides on the lipid rafts. Thus, the anti-ALCAM and anti-CD62P antibodies disrupt an
intricate network of the lipid raft-sensing receptors on the platelets surface.
doi:10.1371/journal.pone.0058979.g004
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recognition of sialated gangliosides by platelets is conserved
between the mouse and human, which has direct implications
for the development of new therapies for neurodegenerative
diseases in patients based on the studies of these structures in
murine models.
The mammalian cells are covered with the carbohydrate
polymers consisting of glycolipids (such as gangliosides) and
glycosylated proteins (glycoproteins and proteoglycans). Together
with cholesterol, glycosylated proteins and lipids are organized as
stable dense areas of the membranes called lipid rafts. The sialic
acid residues are typically the outmost monosaccharide units of
both glycolipids and glycoproteins that often serve as the
recognition sites to which pathogens (such as influenza virus)
attach and infect the target cells [36,52]. Moreover, many
pathogens secrete the neuraminidase that removes sialic acid from
the infected cells [53]. Sialation is important for the homeostasis of
circulating cells, since it is known that asialated platelets or
erythrocytes are eliminated from the blood [54,55]. Recently, it
was shown that asialated proteins and/or cells are recognized by
specific cellular receptors (Ashwell-Morell receptors, AMRs) in the
liver, and the elimination of asialated platelets in the periphery is
an important protective mechanism during systemic infections
[53]. It was also reported that the deregulation of the levels of
expression of sialic acid and sialated gangliosides on the platelets,
cells of blood vessels and tumor cells is associated with other
diseases besides the infection, such as a coronary heart disease,
cancer metastasis and atherosclerosis [7,56–58]. We found that
platelets recognize lipid rafts in the brain, which is known as the
most abundant source of sialated gangliosides, such as GM1,
GT1b, GD3 and GQ [28]. It has been shown that sialated
gangliosides on astrocytes and neurons are important for the
formation of an extracellular matrix and myelin structure as well
as for the neuronal differentiation [29,59]. We also found that the
lipid rafts in the testis and pancreas (which have a tissue barrier
analogous to the BBB) also caused an anaphylactic-like reaction in
mice. A large number of glycosphingolipids which were recog-
nized by platelets in our study are found both in the testis and
pancreas, including GM1, GD3, GT1b and GQ [60–62]. In
addition, we found out that the lipid rafts from the heart and lungs
induced anaphylaxis. The heart, as well as large blood vessels (such
as aorta), contains a large number of gangliosides such as GD3,
which cause a platelet adhesion in vitro [34]. In addition, lungs are
known to contain numerous sialated proteins and glycolipids
(GM1, GD3, GD2) on the columnar epithelial cells which serve as
receptors for the adhesion of respiratory pathogens [36,52].
Interestingly, CD62P binds ganglioside-specific sialated glycoe-
pitopes (39-sialyllactose and a2,8-disialic acid), but not others such
as lactose or 69-sialyllactose. At the same time, P-selectin is only
one of the receptors that can potentially recognize sialated
gangliosides. We propose, that on a molecular level, the
gangliosides in the rigid structures of lipid rafts create multiple
anchor points with several receptors on the surface of the platelets,
known as ‘‘glycosynapses’’ [63] (Figure 7A; see also Supple-
mentary Discussion in File S1). Whereas on a cellular level,
brain lipid rafts provide ‘‘innate danger signals’’ for the immune
system: the recognition of rafts by platelets results in the platelet
degranulation and release of the proinflammatory factors such as
serotonin, chemokine CXCL4/PF4, and cytokine IL-1 culminat-
ing in the subsequent recruitment of the immune cell subsets
(Figure 7B). In addition to PF4 and IL-1, serotonin (5-HT) was
also found to play a proinflammatory role by activating both
innate and adaptive immune cells [64]. Thus we believe that the
brain lipid rafts are a new type of the neuronal damage danger
signals of great importance, since the multiple broad spectrum
agents (NA, CTB, LFA) and specific agents (anti-GQ Abs) that
prevented the platelet-raft interactions substantially ameliorated
the inflammation in the CNS. The CNS inflammation was also
ameliorated in the ST3Gal-V deficient mice that lacked GT1b and
GQ aganliosides, further suggesting that the platelet-rafts interac-
tions contribute to the CNS inflammation in vivo. The subsequent
experiments on the isolation of lipid rafts from the ST3Gal-V
2/2
and WT mice and the administration into the WT mice or
ST3GalV
2/2 mice will further confirm the role of the gangliosides
and platelet-rafts interactions in vivo.
Our findings may also have relevance in other disease processes.
In Alzheimer’s disease and type II diabetes it was shown that the
amyloid precursor protein (APP) peptide directly binds to the
gangliosides in the brain lipid rafts and most probably to the lipid
rafts in the pancreas [65–67]. It is also known that platelets serve
as an abundant source of the APP in the human blood [68]. The
role of the platelets in the atherosclerosis, heart disease and stroke
is well established [69–71], and we now identified the sialated
gangliosides as new potential platelet ligands in these pathologies.
To conclude, our study suggests a novel and important role for the
brain lipid rafts and platelets as therapeutic targets in the diseases
of the CNS and other pathologies.
Methods
Mice
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and CD11b-DTR transgenic (B6.FVB-Tg(IGTAM-DTR/EGF-
P)34Lan/J) mice were purchased from Jackson Laboratories.
FcRc
2/2 (B6.129P2-Tac-Fcer1,tm1.N12) mice were purchased
Figure 5. Platelets penetrate the blood-brain barrier (BBB) and accumulate in the lipid rafts-rich areas in the model of
neuroinflammation. (A–C) The platelets isolated from the CNS of healthy mice or mice with EAE were analyzed by flow cytometry. The platelet-rich
supernatants were prepared from the CNS homogenates, the platelets were stained for CD41 and CD61 (A) The percentages of CD41
+CD61
+ platelets
are depicted in the upper right quadrants of the contour plots. (B) The increase of platelet numbers in the brain and spinal cord in the early stages of
EAE (Mean 6 S.E, five animals per group; **, p,0.01; ***, p,0.001; ****, p,0.0001; when compared to the unmanipulated mice). (C) The
immunofluorescent analysis of the platelet localization within the CNS of WT B6 (C) or the Thy1-YFP reporter mice (D) with EAE on day 6. The CNS
sections were double stained with CTB (green) and anti-CD41 mAbs (red) in (c, left panel) or single stained with anti-CD41 (red) in (c, right panel). The
CD41
+ platelets are indicated by the arrows. (D) The schematic model of platelets topographic disposition in the perivascular space and their
interaction with lipid rafts on astrocytes and neurons as a result of the increased CNS blood vessel permeability. (E–F) The model of the BBB with a
‘‘perivascular space’’ between the monolayer of brain endothelial cells in the top chamber and the astroglial cells in the bottom chamber of the
Transwell system (E). The platelets isolated from the ACTB-GFP transgenic mice were added to the top chamber together with MOG/CFA and/or PTx.
The percentage of the transmigrated GFP
+ platelets is shown in (F). The combined bright field (astroglial cells, grey) and fluorescent images (GFP
+
platelets, green) of the bottom chambers under specified conditions are shown in (G).
doi:10.1371/journal.pone.0058979.g005
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PLOS ONE | www.plosone.org 12 March 2013 | Volume 8 | Issue 3 | e58979Figure 6. Effects of the agents that affect the platelet-lipid raft interactions in the development of EAE. (A,B) EAE in mice treated with
anti-thrombocyte serum (anti-thromocyte), beta subunit of cholera toxin (CTB), neuroaminidase (NA), and Limax flavus agglutinin (LFA) (A) or anti-GQ
(A2B5) antibodies (B). EAE was induced by the immunization of B6 with MOG/CFA as described in Methods. Pertussis toxin (PTx) was administered i.p.
on day 0 and day 2 post-immunization. The anti-thrombocyte serum was injected on day 0, 2, 4 and 8 post-immunization, and CTB, NA and LFA were
injected on days 0, 2, 4, 6 and 8 post-immunization (A). The anti-GQ antibodies were injected on days 0, 2, 4, 8, 10, 12 and 14 post-immunization (B).
The mice were monitored daily and the EAE score was assessed as described in Methods. Mean 6 S.E. of the total number of animals from the three
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purchased from MMRRC. T/B cell deficient NOD/SCID mice
were kindly provided by Dr. Tobias Schatton (BWH, HMS,
Boston MA). MOG-TCR transgenic 2D2 mice were maintained
in our colony. All animal protocols were approved by Harvard
Medical School Animal Care and Use Committee. For experi-
ments that involved pain and/or distress the appropriate
anesthetic and analgesic drugs were used. Euthanasia was
performed using carbon dioxide.
Cell Isolation and Cultures
Mouse neuronal (NIE115 and Neuro-2A), astroglial type I (C8-
D1A), astroglial type II (C8-S), and brain endothelial (bEnd.3) cell
lines were purchased from ATCC. Rat and mouse astroglial and
oligodendroglial primary cells were isolated from the mixed glial
cultures as described [72,73]. Mouse oligodendroglial cells were
also isolated from the adult mouse brains using OptiPrep Density
separate experiments with groups of 7–10 mice in each experiment is shown. (C,D) The flow cytometry analysis of the CNS infiltrating cells isolated
from the mice treated with anti-GQ antibodies. The mononuclear cells were isolated from the CNS of the mice treated with PBS or anti-GQ antibodies
on day 21 after EAE induction, stained for CD11b and CD45 and analyzed by flow cytometry as described in Methods. The staining for CD11b (y-axis)
and CD45 (x-axis) of the CNS mononuclear cells is shown. The percentages of populations of resting CD11b
+CD45
low microglia (left gates),
CD11b
+CD45
hi macrophages (upper right gates) and CD11b
2CD45
hi lymphocytes (lower right gates) are shown in (C). The quantification of the





+ T cells and CD11b
+CD45
hi macrophages were calculated by multiplying the total cell count obtained using a hemocytometer by the
percentage of these cells determined by flow cytometry. Mean 6 S.E. of the group of five animals is shown. (E,F) The EAE disease course (E) and the
quantification of the CNS immune cell infiltrate (F) in the groups of ST3Gal-V
2/2, ST3Gal-V
+/2 and ST3Gal-V
+/+ mice. The EAE was induced and cellular
infiltration was analyzed as in (A) and (D), respectively. The mean 6 S.E. of the total number of animals from the three separate experiments with the
groups of 7–10 mice in each experiment is shown.
doi:10.1371/journal.pone.0058979.g006
Figure 7. Sialated glycolipids are recognized by platelets as ‘‘innate danger signals’’ of a neuronal damage. (A) The proposed model of
brain lipid rafts recognition by the platelet receptors. Multiple receptors on the platelets and an intact rigid structure of brain lipid rafts are required
to form glycosynapses for the coordinated platelet activation and degranulation.The initial recognition of brain lipid rafts involves the interplay of
siglecs and adhesion molecules such as Siglec-H, Siglec-15, ALCAM or other molecules, which results in the recruitment of P-selectin on the surface of
platelets to the site of glycosynapse formation and eventual platelets degranulation. (B) The schematics of the staged neuronal damage detection
process by platelets leading to the recognition of lipid rafts during EAE or neurodegenerative diseases such as MS. In the intact CNS, platelets do not
see lipid rafts of astrocytes and neurons due to the impermeable nature of the BBB. The trauma, infection, neurodegeneration or inflammation
disrupts the structure of neurovascular units, exposing lipid rafts on the surface of astrocytes and neurons to platelets. The platelets then interact
with brain lipid rafts, become activated and secrete proinflammatory cytokines (IL-1) and chemokines (CXCL4/PF4) and serotonin that attract
immunocytes to the lesion site and activate them in situ. Thus platelets serve as the first line sensors and responders in the early stages of neuronal
damage.
doi:10.1371/journal.pone.0058979.g007
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endothelial cells were isolated as described [75,76].
Antibodies, Proteins and Reagents
Anti- GQ (A2B5), GT1b, GD, MAP2, GFAP, galactocer-
ebroside (GC) mAbs were purchased from Millipore. Fluor-
ophore conjugated anti-CD11b, CD18, CD29, CD41, CD45,
CD47, CD54, CD61, CD62P, CD83, CD90, CD106, CD115,
were purchased from BD Biosciences. Conjugated anti-mouse
CD166 (ALCAM) and MHC class II were purchased from
eBiosciences. Non-conjugated anti-ALCAM, anti-CD61 and anti-
CD41 antibodies were purchased from R&D Inc, Serotec and BD
Biosciences, respectively. Antibodies to MHC class II and CD102
were purchased from Biolegend. Anti-CD36, Siglec-1(CD169),
Siglec-4(MAG), PECAM-1 (CD31), Laminin, PDGFR were
purchased from Abcam. Anti-Siglec-H and Ly-6G were purchased
from eBiosciences. Anti-EAAT-2 (GLT-1) and anti-Siglec-15
antibodies were purchased from Santa Cruz. Since the available
anti-Siglec-15 antibodies were not tested by the flow cytometry, we
confirmed the expression of siglec-15 in platelets by Western blot
prior to flow the cytometry studies.
The rabbit anti-mouse thrombocyte serum was purchased from
Accurate Chemical & Scientific Corp. Gangliosides GM1, GM2,
GD1b, GT1b were purchased from Sigma. Asialated GM1
(asialoGM1), GD3 and GQ gangliosides were purchased from
Calbiochem. Cholesterol, phosphatidylcholine, MbCD (methyl-b-
cyclodextrin), CHAPS, Tween 40, Saponin, Triton X-100 and
FITC conjugated subunit B of Cholera Toxin (CTB-FITC),
Thrombin and Fura-2AM were purchased from Sigma.
The ALCAM-Fc fusion protein was purchased from Leinco
Technologies, Inc. The recombinant mouse ALCAM protein
(rmALCAM) was purchased from Sino Biological Inc. The
CD62P-Fc and PSGL-1-Fc fusion proteins were purchased from
R&D.
Lac (Galb1–4Glcb-PAA-Biotin), 69-SLLac (69-sialyllactose-
PAA-Biotin), 39-SLLac (39-sialyllactose-PAA-Biotin), a2,8-DiSL
(Neu5Aca2-8Neu5Aca-sp-PAA-biotin) biotinylated glycopolymers
were purchased from Glycotech Inc.
The enzymes for in vitro treatment of lipid rafts (phospholipase C
from B. cereus, b-galactosidase from Saccharomyces fragilis, endo-b-
galactosidase from Bacteroides fragilis, amyloglucosidase from
Rhizopus sp., lipase from human pancreas, sphingomyelinase from
B. cereus, b-glucosidase from almonds, a-Fucosidase from Xantho-
monas sp., endoglycosidases F1,2,3 from Elizabethkingia meningoseptica,
sulfatase from Aerobacter aerogenes) were purchased from Sigma.
Neuroaminidase (NA) and non-conjugated Cholera Toxin B
subunit (CTB) used for in vivo administration in mice with EAE
were purchased from Sigma. Limax flavus agglutinin (LFA) was
purchased from EY Laboratories Inc. To treat mice with EAE,
NA (0.4 U/mouse), CTB (40 mg/mouse), LFA (0.4 mg/mouse)
were injected i.p. on day 0, 2, 4, 6 and 8 after EAE induction.
Anti-thrombocyte serum was injected i.v. on day 0 and 2 (30 ml/
mouse) and then i.p. (40 ml/mouse) on day 4 and 8 after EAE
induction. Anti-GQ (A2B5) Abs were injected i.v. (40 mg/mouse)
on day 0, 2, 4, 6, 8, 10, 12 and 14 after EAE induction.
For the depletion of cells in vivo 0.5 mg/mouse of antibodies
(injected i.p) or 30 ml of the anti-thrombocyte serum (injected i.v.)
were used. Antibodies were injected i.p. 24 hours or i.v. 4 hours
prior to the analysis. The extent of depletion of platelets by the
anti-thrombocyte serum or anti-CD61 mAbs was assessed by
counting the platelets in the peripheral blood. Platelets counts
were decreased with both antibodies from 5–8 to 0.1–0.3 (610
5/
ml). The granulocyte depletion was performed by the treatment
with anti-Ly-6G antibodies. The granulocyte counts in the
peripheral blood were assessed by microscopy after the lysis of
erythrocytes, fixation of the cells with methanol and H&E staining.
The granulocyte numbers were decreased from 5–7 to 0.03–0.1
(610
6/ml). For blocking of the receptors in vivo 0.25 mg/mouse of
antibodies were injected i.v. 30 minutes prior to the injection of
lipid rafts. For the depletion of macrophages in CD11b-DTR
transgenic mice [77], 500 ng/mouse of diphtheria toxin (DTx) was
injected i.p. every other day for 12 days. The extent of
macrophage depletion by DTx was assessed by FACS by
measuring the percentage of CD11b
+F4/80
+ cells in the peritoneal
cavity and in the peripheral blood. We found that the percentages
of CD11b
+F4/80
+ cells decreased from 4665% to 662% in the
peritoneal cavity and from 863% to 261% in the peripheral
blood. The depletion of macrophages with liposomes with
bisphosphonate clodronate was performed as described [78]. We
found that the percentage of CD11b
+F4/80
+ macrophages
decreased from 762% to 161% in the peripheral blood as
determined by FACS.
Isolation of Lipid Rafts
Lipid rafts from the mouse brain, spinal cord, liver, lungs, testis,
eyes, thymus, spleen, kidney, ovaries, pancreas, adrenal glands and
heart were isolated by the homogenization of 0.2 mg of wet tissue
per 1 ml of PBS with 0.5% Triton X-100 (Sigma). After which, the
homogenate was centrifugated at low speed (250 g) for 5 minutes
and the supernatant was filtered through 0.4 m and nylon filter
(Millipore) and washed two times with PBS by the centrifugation
at high speed (16,000 g) for 10 minutes. The rafts were injected i.v.
100 ml per mouse. The lipid rafts were also obtained by a
detergent-free method using recently published protocol with
modifications [79]. Briefly, 0.5 mg of the brain wet tissue was
homogenized in 1 ml of PBS, and after the centrifugation at 400 g
for 10 min, the supernatant was filtered through 0.4 m and then
through 0.2 m filter (Millipore) and injected i.v. 200 ml per mouse.
In some experiments, lipid rafts were isolated from the cultured
cells, frozen samples of the human brain, rat brain, or frozen fish
brain (Atlantic Cod and Shark), as described above. To purify the
lipid rafts from the human white and gray matter of the brain,
unidentified frozen autopsy samples from New York tissue bank
were used. The work with human autopsy samples was approved
by HMS review board committee. The gray and white matters
were dissected, the lipid rafts were isolated by the homogenization
in PBS with 0.5% Triton X-100. To isolate the lipid rafts from a
myelin fraction of the rat brain (Lewis rats), the myelin fraction of
the homogenized rat brain was isolated using a sucrose gradient
and ultracentrifugation as described [80], and after that the lipid
rafts were prepared using PBS with 0.5% Triton X-100. The
amount of lipid rafts was quantified using a kit for the
measurement of the concentration of phospholipids (Wako
Chemicals) and injected i.v. at 1 mg of phospholipids per mouse.
Fractionation and Quantification of Lipid Rafts
Lipid rafts were isolated using PBS with 0.5% of Triton X-100
and analyzed using a 40%/35%/5% discontinuous sucrose
gradient and ultracentrifugation (38,000 g for 19 hours) on the
Beckman ultracentrifuge [79,81]. Four or 11 fractions were
collected and the concentration of phospholipids, cholesterol were
assessed using the kits from BioVision and Wako Chemicals and
the amount of the transferin receptor (Tfr) was assessed by
Western blot analysis.
Assessment of the Anaphylactic-like Reaction in Mice
The mice were restrained and injected i.v. with the indicated
amounts of lipid rafts and immediately released. The mice were
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temperature were assessed and then overlooked for an additional
hour to ensure their recovery. The clinical scores were assessed as
follows: 1) restless behavior; 2) loss of consciousness; 3) dyspnea; 4)
death. The body temperature was measured using a digital
precision thermometer equipped with a rectal probe (YSI
Sensors&Instruments). The positive anaphilactogenic effect was
registered at a score of one or higher. When we monitored the
symptoms during a ten-minute period, we observed that the
clinical symptoms typically reached the maximum in five minutes
after the administration (Figure S1a in File S1) after which the
mice started to recover. The anaphylactic symptoms were also
accompanied by hypothermia (Figure S1b in File S1), a known
feature of an anaphylactic shock. After a 10-minute observation
the mice were administrated with analgesic agents and saline, and
monitored for several hours to ensure complete recovery. The
histamin level was measured in the plasma in a group of 5–7
unmanipulated mice and in a group of 5–7 mice after the
administration of lipid rafts using an ELISA kit from GenWay.
Model Lipid Rafts
The model lipid rafts were prepared as described [82] with
modifications. Briefly, 1 mg of a particular ganglioside (asia-
loGM1, GM1, GD1b, GD3, GM2, GT1b, GQ), or 1 mg of
galactosylcerebroside (GC) or 1 mg phosphatidylcholine (used as a
background control, Bkg) were mixed with 0.5 mg of phosphati-
dylcholine and 6 mg of cholesterol, dissolved in 1 ml of
chloroform/methanol (1:1) and allowed to dry on a SpeedVac
for 1–2 hrs. The lipids were then resuspended in 1 ml of PBS with
0.5% Triton X-100, vortexed (5 min) and sonicated (3 min)
several times until a homogeneous suspension is obtained. The
suspensions were centrifuged at 16,000 g for 10 min, the
supernatants were completely decanted and pellets were resus-
pended in 1 ml of PBS. The suspension of model rafts was injected
i.v. 250 ml/mouse or used for the in vitro serotonin release assay
described below.
Platelet Isolation and Analysis
For the isolation of platelets from the periphery, the blood was
collected and 0.38% sodium citrate was added to the tubes to
prevent coagulation. The platelet rich plasma (PRP) was obtained
by a low speed centrifugation (250 g) for 5 minutes. The PRP was
used for the Flow Cytometry and serotonin release assay. For the
FACS analysis, the percentage of CD41
+CD61
+ platelets was
analyzed in the forward/side scatter ‘‘platelet’’ gate as described
[8]. For the platelet adhesion assay and Western blot analysis, the
platelets were further purified by filtration of the PRP through a
Sepharose 40 (Sigma) column with BSA as described [83].
For the isolation of platelets from the CNS, the mice were
perfused with PBS and the brains or spinal cords were dissected,
homogenized, and centrifuged at a low speed (250 g) for 5
minutes. The Platelet rich supernatant of the CNS homogenate
was used for the FACS analysis of platelets similarly to the FACS
analysis of platelets in the PRP by determining the percentage of
CD41
+CD61
+ platelets in the ‘‘platelet’’ forward/side scatter gate.
Platelet Serotonin, PF4/CXCL4 and IL-1a and Release
Assays
300 ml of the platelet rich plasma were mixed with 60 ml of the
brain lipid rafts or PBS and incubated for 30 minutes for serotonin
and 1–4 hours for PF4 and IL-1a at +37uC. Then the samples
were centrifuged at 16,000 g for 7 minutes at +4uC and 100 ml
supernatant (platelet-free plasma) was used for serotonin (Gen-
Way), mouse PF4/CXCL4 (Uscn Life Science) or IL-1a
Biolegend) ELISAs according to the manufacturer’s recommen-
dations. For the blocking experiments, 250 ml of the platelet rich
plasma were mixed with 50 ml of the blocking antibodies or PBS
and incubated at +20uC for 15 min before the addition of the
brain lipid rafts.
Platelet Adhesion Assay
The adsorption of gangliosides to a 96 well flat bottom plate was
performed as described [84]. Briefly, gangliosides were mixed with
cholesterol, dissolved in ethanol, added 150 ml/well to the plate
and allowed to dry overnight at 20uC. The next day the plates
were first washed with water and then in Tyrode solution
(137 mM NaCl; 2.8 mM KCl; 1 mM MgCl2; CaCl2 2 mM;
0.4 mM NaH2PO4; 12 mM NaHCO3; 5.5 mM glucose; 5 mM
HEPES 0.35% BSA, pH=7.4). After that the plates were
incubated with Tyrode solution 100 ml/well for 2 hrs at 37uC
before the addition of platelets. The platelets were isolated by
filtration of the PRP from the DsRed tg mice through a Sephadex
40 column saturated with PBS and added to the plates with
adsorbed ganagliosides as described [34]. After 2 hours of
incubation at 37uC the plate was gently washed three times with
a Tyrode solution and the fluorescence was measured on the
TECAN multichannel spectrofluorometer.
EAE Induction
EAE was induced by a subcutaneous immunization with 150 mg
MOG in 4 mg/ml CFA of 8–12–week-old B6 mice as was
described previously [85]. Pertussis toxin (PTx) was given i.p.
(150 ng/mouse) on days zero and two post-immunization. The
mice were observed for the signs of disease starting on day five
post-transfer, and the disease severity was scored on a numerical
scale 0–5 as follows: 0) no disease; 1) weak tail or wobbly walk; 2)
hind limb paresis; 3) hind limb paralysis; 4) hind and forelimb
paralysis; and 5) death or euthanasia due to humane reasons.
When we examined the mice with EAE after the platelet
depletions, we did not find signs of spontaneous hemorrhages in
the brain, spinal cord or other organs except for the intestines and
skin, where bleeding was observed in 30–40% of mice. A similar
percentage of mice with depleted platelets that were immunized
with CFA alone also had intestinal/skin bleeding which was
associated with ,30% mortality. To decrease the rate of mortality
we lowered the dose of CFA from 4 mg/ml to 3 mg/ml and kept
the same amount of MOG peptide and PTx. The decrease in CFA
eliminated the symptoms of skin and intestinal bleeding and
decreased the rate of mortality to 5–10%, a level similar to the
non-immunized mice with depleted platelets. The decrease of
CFA for immunization slightly decreased the clinical EAE scores
in the control group of mice from a typical score of 2 to a score 1.5
at the peak of EAE, but did not affect the incidence or the onset of
the disease.
For the induction of EAE without PTx, the mice immunized
with MOG were injected 75 ml/mouse i.v. of brain lipid rafts or
PBS; or were injected i.c. 20 ml/mouse PRP or PBS on day 0 post-
immunization.
Flow Cytometry
The multicolor flow cytometry analysis was conducted in the
Flow Cytometry core facility of The Center for Neurologic
Diseases (Brigham and Women’s Hospital, Harvard Medical
School) following the standard procedures. The isolation of cells
from the CNS and spleen and the flow cytometry analysis were
performed as described [85]. The flow cytometry analysis was
conducted on the LSR II Cytometer. The imaging cytometry was
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TM cytometer (Amnis Inc.) in Flow
and Imaging Core Facility of Immune Disease Institute (Harvard
Medical School). The images of cells were analyzed using the
Imagestream Data Exploration and Analysis Software (IDEAS).
For the analysis of brain lipid rafts, the rafts were centrifuged at
16,000 g for 10 minutes and resuspended in the 70% goat serum
in PBS for blocking of the non-specific staining. After 30 min of
incubation in the goat serum, FITC conjugated CTB (that stain
GM1), anti-GM2, anti-GD1b, anti-GD3 anti-GT1b, anti-A2B5
(that stain GQ), anti-GC, or anti-GLT-1 antibodies were added to
the samples and incubated for 20 min at room temperature,
washed once with PBS, after which the lipid rafts were centrifuged
at 16,000 g for 10 minutes, resuspended in PBS with the 70% goat
serum and secondary antibodies and incubated for 20 minutes at
room temperature. Finally the samples were washed twice with
PBS and fixed in 1% paraformaldehyde in PBS and analyzed on
the LSR II cytometer. For the FACS analysis of lipid rafts, we
adapted a published method for the detection of small viral
particles of the sizes less than 200 nm [86]. The FSC and SSC
parameters were set to a logarithmic scale and the threshold
decreased. To ensure we did not detect the noise in our FSC/SSC
gate, we used staining for GM1 with CTB-FITC, which gave a
very bright fluorescent signal in the FL-1 channel. We found that
97–99% of the lipid rafts in the FSC/SSC gate were GM1
positive.
For the analysis of platelets from the periphery, 1 ml of anti-
CD41, anti-CD61 and either of other surface marker antibodies
(CD54, CD62P, CD83, CD102, CD106, CD166, CD169, Siglec-
H, Siglec-4) at proper dilution were added to 200 ml of PRP,
incubated 20 min at +20uC, the cells were fixed by adding of 1 ml
of 1% paraformaldehyde in PBS and analyzed by the three-color
flow cytometry. For the analysis of platelets from the brain or
spinal cord, the brains or spinal cords were homogenized and
centrifuged at a low speed (250 g). After that, 200 ml of the platelet
rich supernatant of the CNS homogenate was mixed with 200 ml
of the normal goat serum and incubated at +20uC for 15 min,
after which 3 ml of anti-CD41 and anti-CD61mAbs were added.
After the incubation with antibodies for 10–15 min at +20uC, the
cells were fixed in 1 ml of 1% paraformaldehyde in PBS. For the
assessment of platelets and platelet-derived microparticles, the
forward and size scatter parameters on the flow cytometer were set
to a logarithmic scale and the CD61
+CD41
+ gated cells in the
‘‘platelet’’ forward/size scatter gate were analyzed as platelets, and
the CD41
+ particles in the sub-platelet ‘‘microparticle’’ forward/
size scatter gate were determined as platelet-derived microparticles
as described [8].
CD4 T cell Recall Response
The MOG-TCR transgenic 2D2 mice were immunized with
150 mg MOG in 4 mg/ml CFA, and seven days later the CD4
+ T
cells were isolated from the spleen by negative selection using
magnetic beads as described [85]. Anti-GQ (A2B5) mAbs or PBS
were injected i.v. (40 mg per mouse) on day 0, 2, 4 and 6 post-
immunization. The CD4 T cells were incubated with irradiated
splenocytes from the B6 mice for 48 hours in the presence of
MOG35–55 (5–20 mg/ml) with or without anti-GQ mAbs (5–
10 mg/ml), after which the level of proliferation was assessed by
the flow cytometry examining the bromodeoxyuridine (BrdU)
labeling of the cells in vitro as described previously [85].
Platelet Transmigration Assay
The brain endothelial cell line (bEnd.3) was grown for 72 hours
to reach the confluence in the top chamber of the transwell system
(the membrane inserts) for 24 well plate with 5 mm pore size
(Corning). The astroglial cells (C8-D1A) were grown in the bottom
chamber at the density close to the confluent for 72 hours. The
barrier integrity was checked by a fluorescently labeled dextran
flux to the lower chamber and measured using a spectrofluorom-
eter as described [41]. The platelets isolated from the ACTB-GFP
transgenic mice by centrifugation were added to the top chamber.
For the activation of endothelial cells PTx (200 ng/ml) and/or
MOG (40 mg/ml) with CFA (50 mg/ml) were added to the cultures
as described [41] simultaneously with the platelets. After the
incubation in the CO2 incubator for 18 hours, photographs from
the bottom chambers were taken using an inverted fluorescent
microscope. After that the GFP
+ platelets were washed from the
astroglial monolayer, the supernatant was plated at 200 ml/well in
triplicate in a flat bottom 96 well plate for the fluorescence
measurement and read on a TECAN spectrofluorometer (excita-
tion at 488 nm, emission at 525 nm).
CD62P (P-selectin) and CD166 (ALCAM) Binding Assays
To assess the ability of CD62P and CD166 to bind sialated
glycoepitopes, streptavidin was adsorbed to flat bottom 96 well
high-binding plates (Nunk), and after washing and blocking with
TBS buffer with 2% BSA, Lac, 69-SLLac, 39-SLLac and a2,8-
DiSL biotinylated glycopolymers were added at 10 mg/ml to the
plate. After several washes, the CD62P-Fc or CD166-Fc fusion
proteins (at concentrations of 0–5 mg/ml) were incubated with the
immobilized probes. After the incubation and washing, the
antibodies that recognize a human Fc fragment conjugated with
AP (Acris) were used for detection. Finally the plates were
incubated with an AP substrate and analyzed on a TECAN
spectrophotometer (absorbance at 405 nm). To assess the of ability
of CD62P to bind ALCAM, the recombinant mouse ALCAM
protein was adsorbed to the plate, and CD62P-Fc and the
antibodies that recognize the human conjugated with AP Fc
fragment were used as described above.
Immunofluorescent Microscopy
The normal mice or mice with EAE were perfused first with
PBS, and then 1% of paraformaldehyde in PBS. The brains/spinal
cords were dissected from the mice or human brain tissue samples
and fixed in 1% of paraformaldehyde in PBS overnight, and then
dehydrated in 30% sucrose for 2–3 days. 10 m-thick frozen sections
were prepared and stained for GM1 (with CTB-FITC or CTB-
biotin combined with SA-AF594), and GFAP, or MAP2, or
Laminin, or CD31, or PDGFR or CD41 combined with the
secondary antibodies conjugated with AF594.
Statistical Analysis
Student’s t-test was used to validate the significance of the
observed differences. A p-value of less than 0.05 was considered
statistically significant.
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Video S1 Clinical symptoms of the anaphylactic-like
reaction induced by the brain lipid rafts. Video starts 45
seconds after i.v. administration of brain lipid rafts.
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